Why the study?
Does Neuropeptide Y potentiate the pressor effects of vasoconstrictive agents and influence the dilatation effects of endothelin-1 in rats with congestive heart failure?
Does Neuropeptide Y potentiate the pressor effects of vasoconstrictive agents and influence the dilatation effects of endothelin-1 in rats with congestive heart failure?
Neuropeptide Y potentiates the pressor effects of angiotensin II and reduces the vasodilatation effects of endothelin-1 in rats with CHF, potentially contributing to increased vascular tone.
No takes yet. Share an insight, caveat, or question.
NPY effects on vasoconstrictors in CHF rats are hypothesis-generating; leaves open relevance to human vascular regulation or therapy.
Feng et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: